Effect of transdermal testosterone replacement in hypogonadal men with decreased insulin sensitivity

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 20 Aug 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Testosterone (Primary)
Indications Hypogonadism
Focus Adverse reactions; Pharmacogenomic; Therapeutic Use
Acronyms TIMES-2
Sponsors Kyowa Kirin

Most Recent Events

06 Jan 2012 Actual end date changed from Jun 2008 to Aug 2008 as reported by ISRCTN: Current Controlled Trials
30 Mar 2011 Results have been published in Diabetes Care, according to a ProStrakan media release.
18 Jun 2008 Testosterone gel is expected to be filed for approval in the US in the second half of 2008, according to a ProStrakan media release..

Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

IP authentication when working within your organization’s network.
Login with username/password or try access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days.
Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Contact your organization’s admin about adding this content to your AdisInsight subscription
Buy a PDF version of the profile.
Request a free trial

Welcome to AdisInsight